Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus or to help lose weight in adults with an elevated BMI.

Semaglutide increases insulin production, lowers blood sugar levels and slows the rate of gastric emptying. It also appears to enhance pancreatic cell growth, which helps insulin production.

Semaglutide prevents blood sugar spikes and allows our bodies to process the foods we eat, decreasing appetite and overall calorie consumption throughout the day.

Individuals have demonstrated rapid changes in body weight with little lifestyle modification. However, when combined with a healthy diet and exercise, the fat melts right off!

Through iThriveMD, Revive clients can purchase a membership. The semaglutide membership is $299 billed monthly, Radiance Members receive a 10% discount and includes:

– Complimentary consultation

– Weekly injections (4 total)

– Monthly check-in with a provider

– Lab analysis

– Personalized weight loss plan

In addition, individuals may anticipate the following costs:

‍Initial Blood Work ($36 – $185)
– Comprehensive lab panel to assess hormone levels, immune function, and metabolism to inform treatment plans. 
– Will be repeated every 6 months for monitoring.

Individuals typically report little to no side effects. The most common side effects are often temporary and may include: Nausea, vomiting, diarrhea, stomach discomfort, constipation, dizziness, or tiredness.

Nausea or stomach discomfort typically decreases as your body adapts to semaglutide over the course of several weeks. If you do experience any side effects, speak with your provider about your options to alleviate these symptoms during your treatment.

If any side effects become worse or do not subside with continued use, contact your medical provider promptly.

GLP-1 agonists, like Semaglutide, target inflammatory pathways in the body that contribute to tissue damage and oxidative stress.

Neurotransmitters are also targeted, resulting in a decrease in appetite and improved satiation (fullness). Digestion of food in the GI tract is slowed, altering how quickly the stomach contents are emptied into the small intestine resulting in better satiation.

Further, GLP-1 agonists have shown to increase insulin secretion and decrease glucagon levels in the body, improving overall blood sugar regulation.